IBO — Impact Biomedical Cashflow Statement
0.000.00%
Last trade - 00:00- $9.04m
- $18.96m
Annual cashflow statement for Impact Biomedical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.815 | -1.85 | -7.25 | -4.41 | -24.8 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | — | — | 4.1 | 0 | 20.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.002 | 0.102 | 0.421 | 0.436 | -0.608 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -0.899 | -2.03 | -2.24 | -2.85 | -3.92 |
| Capital Expenditures | — | — | -0.276 | -0.018 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.632 | -9.46 | -0.073 | 0.003 | 0.002 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.632 | -9.46 | -0.349 | -0.015 | 0.002 |
| Financing Cash Flow Items | 0.435 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.49 | 11.5 | 2.55 | 2.87 | 5.92 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.036 | -0.026 | -0.044 | -0.001 | 2 |